Abstract: |
In recent decades, radiopharmaceuticals-particularly those for PET imaging-have become vital clinical tools in oncology. In this chapter, we seek to provide a bird's-eye view of the current landscape of emergent PET radiopharmaceuticals, specifically those that have been the subject of multiple clinical trials but have yet to be approved by regulatory agencies for routine use. We will begin with a brief discussion of the fundamental anatomy of radiopharmaceuticals and then embark upon detailed examinations of several agents designed to facilitate the imaging of the aberrant amino acid transport, cellular metabolism, lipid biosynthesis, and cell surface receptors of malignant tissues. Particular focus will be dedicated to the early phase clinical trials in which these radiopharmaceuticals have been employed. This chapter will conclude with an examination of a particularly exciting recent trend in nuclear medicine: the advent of radiotheranostics. © Springer Nature Switzerland AG 2022. |